StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN)

Equities research analysts at StockNews.com assumed coverage on shares of Lipocine (NASDAQ:LPCN – Get Free Report) in a research report issued on Tuesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock. Lipocine Stock Performance Shares of LPCN opened at $3.90 on Tuesday. The stock has a market cap of $20.75 million, […]

Leave a Reply

Your email address will not be published.

Previous post Wedbush Reiterates “Outperform” Rating for Inozyme Pharma (NASDAQ:INZY)
Next post Cloudbuy (LON:CBUY) Stock Crosses Below 200-Day Moving Average of $0.15